Semaglutide can improve liver disease without major weight loss, researchers at Toronto's Sinai Health reported in a study published in Cell Metabolism. The finding challenges a long-held assumption about how the drug works and suggests the medicine’s benefit in MASH is not limited to the scale.
Dr. Daniel Drucker, who has spent decades helping shape the science behind GLP-1 medicines, said patients who lose very little weight see the same reductions in liver inflammation, scarring and enzyme levels as those who lose a great deal of weight. “We’ve seen in clinical trials that patients who lose very little weight see the same reductions in liver inflammation, scarring and enzyme levels as those who lose a great deal of weight. Now we know why,” he said.
The study found semaglutide acts directly on a subset of liver cells, identifying two cell types that carry semaglutide receptors: liver sinusoidal endothelial cells and immune T cells. The endothelial cells made up only about 3% of liver cell volume, yet they were the key driver of the drug’s liver benefits. In another experiment, Dr. Gonzalez-Rellan showed that semaglutide reversed MASH in mice that lacked the brain receptors that control appetite, a result that pushed the research away from the idea that liver improvement was simply a byproduct of eating less.
That matters because semaglutide and other GLP-1 medicines were first developed for type 2 diabetes and obesity, then became known for lowering blood sugar and promoting weight loss. MASH is closely linked with obesity and type 2 diabetes, so treatment has typically included lifestyle changes aimed at reducing weight. The new work suggests the liver response can arrive even when that larger metabolic shift does not.
MASH is a severe form of fatty liver disease in which fat buildup, inflammation and tissue scarring can progress to cirrhosis and liver failure, and it affects about 25% of Canadian adults. The study gives doctors a better explanation for why GLP-1 medicines can help patients whose weight changes are modest, and it strengthens the case that these drugs have a direct role in liver disease rather than only an indirect one. For patients and physicians, the answer is now clearer: the liver benefit does not depend on weight loss alone.
